NERV.NASDAQMinerva Neurosciences, INC
10-K/A: Minerva Neurosciences Files Amendment to 10-K Report, Updates Executive and Director Information
Sentiment:
10-K/A Amendment
Minerva Neurosciences files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and executive compensation.
Summary
- Minerva Neurosciences filed Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2024.
- The amendment includes information required by Items 10 through 14 of Part III of Form 10-K, which were initially omitted.
- Item 15 of Part IV of the Original 10-K was amended to update the exhibit list.
- The company is including currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- The amendment does not reflect events occurring after the filing of the Original 10-K or modify disclosures affected by subsequent events.
Sentiment
Score: 7
Explanation: The document is primarily factual and descriptive, with a neutral tone. The inclusion of previously omitted information is a positive step towards transparency. However, the need for an amendment and the presence of related party transactions introduce some level of caution.
Positives
- The company is providing greater transparency by including previously omitted information in its amended 10-K filing.
- The company has a clawback policy in place, allowing for the recovery of compensation in certain circumstances.
- The Board has determined that all non-employee directors are independent, ensuring objective oversight.
- The Audit Committee has a pre-approval policy for audit and non-audit services, promoting auditor independence.
Negatives
- The need to file an amendment suggests potential oversights in the original filing.
- The company is paying significant amounts for consulting services to related parties, which could raise concerns about conflicts of interest.
Risks
- The company's reliance on consulting services from related parties could pose a risk if these services are not provided on an arm's-length basis.
- The potential for conflicts of interest in related person transactions could negatively impact the company's financial performance and reputation.
- The company's success depends on retaining key executive officers and directors.
Future Outlook
The company has agreed to use commercially reasonable efforts to keep the registration statement effective until the earlier of (i) the third anniversary of the effective date of the initial registration statement covering the Registrable Securities; (ii) the date all Shares and all shares of common stock underlying the pre-funded warrants may be sold under Rule 144 of the Securities Act of 1933, as amended, without being subject to any volume, manner of sale or publicly available information requirements; or (iii) immediately prior to the closing of a Change of Control (as such term is defined in the Securities Purchase Agreement).
Industry Context
The document provides insight into the compensation structures and corporate governance practices within a publicly traded biopharmaceutical company, which is useful for benchmarking against industry peers. The presence of significant shareholders like Boehringer Ingelheim and Federated Hermes is indicative of institutional interest in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages appear to be in line with industry standards for similarly sized biopharmaceutical companies.
- Director compensation, including cash retainers and equity grants, is consistent with practices observed at other Nasdaq-listed companies.
- The presence of a clawback policy and a related person transaction policy reflects adherence to corporate governance best practices.
- The involvement of major pharmaceutical companies like Boehringer Ingelheim as investors and board observers is a common occurrence in the biotech industry, providing strategic insights and potential collaboration opportunities.
Next Steps
- The company will continue to monitor and manage related person transactions in accordance with its policy.
- The company will ensure compliance with Nasdaq listing standards regarding director independence.
- The company will continue to execute its business strategy and pursue regulatory approvals for its product candidates.
Key Dates
| Date | Description |
|---|---|
| 2007-08-30 | License Agreement between Mitsubishi Pharma Corporation and the Registrant f/k/a Cyrenaic Pharmaceuticals, Inc., dated as of August 30, 2007 |
| 2008-09-01 | License Agreement between Mitsubishi Tanabe Pharma Corporation and the Registrant as successor in interest to Sonkei Pharmaceuticals, Inc., dated as of September 1, 2008 |
| 2009 | Mr. Hasler has served as Chairman of the Board of HBM Healthcare Investments AG, a SIX Swiss Exchange listed company, since 2009. |
| 2010-07 | Dr. Remy Luthringer has provided services to us since July 2010, first as a consultant |
| 2010 | Mr. Race has provided services to us since July 2010, first as a consultant |
| 2010-06 | Mr. Race served as the Chief Executive Officer and acting Chief Financial Officer of Funxional Therapeutics Ltd., a clinical stage pharmaceutical company which was spun out of Cambridge University, UK, from June 2010 to November 2013. |
| 2010 | He was also a board member and chairman of the Audit Committee of Amarin Corporation, a publicly traded biopharmaceutical company from 2010 to 2023. |
| 2011-06-16 | Amendment to License Agreement between Mitsubishi Tanabe Pharma Corporation and the Registrant f/k/a Cyrenaic Pharmaceuticals, Inc., dated as of June 16, 2011 |
| 2014-01-20 | Second Amendment to License Agreement between Mitsubishi Tanabe Pharma Corporation and the Registrant, dated as of January 20, 2014 |
| 2014-01-20 | Amendment to License Agreement between Mitsubishi Tanabe Pharma Corporation and the Registrant, dated as of January 20, 2014 |
| 2014-01 | Frederick Ahlholm has provided services to us since January 2014, first as a consultant |
| 2014-02-11 | Share Purchase Agreement between the Registrant, Mind-NRG SA and Various Shareholders dated as of February 11, 2014 |
| 2014-02-13 | Co-Development and License Agreement between Janssen Pharmaceutica, N.V. and the Registrant, dated as of February 13, 2014 |
| 2014-05 | Dr. Remy Luthringer was named our President and Chief Executive Officer in November 2014, and served as President until December 2017. |
| 2014-05 | Dr. Remy Luthringer has provided services to us since July 2010, first as a consultant and then as an employee beginning in May 2014. |
| 2014-05 | Geoffrey Race has provided services to us since July 2010, first as a consultant and then as an employee beginning in May 2014. |
| 2014-05 | Mr. Race most recently held the positions of the Companys Executive Vice President and Chief Financial Officer, from May 2014 to October 2021, and Chief Business Officer from January 2016 to October 2021. |
| 2014-05 | Frederick Ahlholm most recently held the positions of the Companys Vice President and Chief Accounting Officer from July 2014 to October 2021, and Senior Vice President of Finance from May 2015 to October 2021. |
| 2014-07 | Jan van Heek has served on our Board since July 2014. |
| 2014-07 | Frederick Ahlholm most recently held the positions of the Companys Vice President and Chief Accounting Officer from July 2014 to October 2021, and Senior Vice President of Finance from May 2015 to October 2021. |
| 2014-11 | Dr. Remy Luthringer was named our President and Chief Executive Officer in November 2014, and served as President until December 2017. |
| 2014-11 | Dr. Remy Luthringer has served on our Board since November 2014. |
| 2015-03-13 | Form of Securities Purchase Agreement between certain investors referenced therein and the Registrant, dated as of March 13, 2015 |
| 2015-03-13 | Form of Registration Rights Agreement between certain investors referenced therein and the Registrant, dated as of March 13, 2015 |
| 2015-05 | Dr. Fouzia Laghrissi-Thode has served on our Board since May 2015. |
| 2015-05 | Frederick Ahlholm most recently held the positions of the Companys Vice President and Chief Accounting Officer from July 2014 to October 2021, and Senior Vice President of Finance from May 2015 to October 2021. |
| 2015-04-21 | Second Amendment to License Agreement between Mitsubishi Tanabe Pharma Corporation and the Registrant, dated as of April 21, 2015 |
| 2015-11 | Dr. David Kupfer has served on our Board since November 2015. |
| 2016-01 | Mr. Race most recently held the positions of the Companys Executive Vice President and Chief Financial Officer, from May 2014 to October 2021, and Chief Business Officer from January 2016 to October 2021. |
| 2016-03-17 | Common Stock Purchase Agreement, dated March 17, 2016, by and between David Kupfer and the Registrant |
| 2016-08-01 | Employment Agreement, dated as of August 1, 2016, by and between Mind-NRG SARL and Dr. Remy Luthringer |
| 2016-08-01 | Employment Agreement, dated as of August 1, 2016, by and between Mind-NRG SARL and Geoffrey Race |
| 2016-08-01 | Employment Agreement, dated as of August 1, 2016, by and between the Registrant and Frederick Ahlholm |
| 2016-12-16 | Form of Restricted Stock Unit Agreement under the Amended and Restated 2013 Equity Incentive Plan of the Registrant |
| 2017-03-07 | Amended and Restated Non-Employee Director Compensation Plan Approved: March 7, 2018 Effective: April 1, 2018 |
| 2017-06-13 | Amendment No. 1 to Co-Development and License Agreement dated June 13, 2017, by and between the Registrant and Janssen Pharmaceutica NV |
| 2017-12 | Dr. Remy Luthringer was named our President and Chief Executive Officer in November 2014, and served as President until December 2017. |
| 2017-12 | Hans Peter Hasler has served on our Board since December 2017. |
| 2018-04-01 | Amended and Restated Non-Employee Director Compensation Plan Approved: March 7, 2018 Effective: April 1, 2018 |
| 2018-09 | Mr. Hasler has served as the Chairman of Shield Therapeutics, an AIM-listed specialty-pharma company, since September 2018 |
| 2019-09-18 | Commercial Supply Agreement by and between the Registrant and Catalent Germany Schorndorf GmbH, dated September 18, 2019 |
| 2020 | Until 2020, Mr. Hasler served as the Chief Executive Officer of Vicarius Pharma AG, a privately held company that provided strategic options to non-European bio-pharma companies bringing late-stage assets to the European market. |
| 2020-06-24 | Settlement Agreement, dated as of June 24, 2020, by and between the Registrant and Janssen Pharmaceutica, N.V. |
| 2021-01-15 | Royalty Purchase Agreement, dated as of January 15, 2021, by and between the Registrant and RPI 2019 Intermediate Finance Trust (redacted) |
| 2021-03 | Mr. Hasler has served as a Director of Gain Therapeutics, a Nasdaq-listed biotechnology company, since March 2021. |
| 2021-05-12 | Remy Luthringer Supplemental Retention Benefits Letter Agreement (redacted) |
| 2021-09-15 | Dr. Saoud resigned from the position of Senior Vice President, Head of Research and Development, effective September 15, 2021. |
| 2021-09-15 | Dr. Saouds consulting services will end on April 30, 2025, subject to termination or renewal. |
| 2021-10-11 | First Amendment to the Employment Agreement of Geoff Race by and between Mind-NRG SARL and Geoff Race, effective October 11, 2021 |
| 2021-10-11 | Amended and Restated Employment Agreement by and between Minerva Neurosciences, Inc. and Frederick Ahlholm, effective October 11, 2021 |
| 2021-10 | Mr. Race most recently held the positions of the Companys Executive Vice President and Chief Financial Officer, from May 2014 to October 2021, and Chief Business Officer from January 2016 to October 2021. |
| 2021-10 | Frederick Ahlholm most recently held the positions of the Companys Vice President and Chief Accounting Officer from July 2014 to October 2021, and Senior Vice President of Finance from May 2015 to October 2021. |
| 2022-06-17 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant 8-K 001-36517 3.1 June 17, 2022 |
| 2022-07-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain First Amendment effective July 1, 2022 |
| 2022-09-14 | Open Market Sale Agreement, dated as of September 14, 2022, by and between the Registrant and Jefferies LLC |
| 2022-12-13 | First Amendment to the Employment Agreement of Remy Luthringer by and between Mind-NRG SARL and Remy Luthringer, effective December 13, 2022 |
| 2023-01-01 | Effective as of January 1, 2023 and through March 15, 2023, Dr. Saoud was entitled to receive $24,000 for up to fifteen hours of consulting services per week for a four-week period. |
| 2023-01-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Second Amendment effective January 1, 2023 |
| 2023-03-06 | Second Amendment to the Employment Agreement of Remy Luthringer by and between Mind-NRG SARL and Remy Luthringer, effective March 6, 2023 |
| 2023-03-16 | Effective March 16, 2023 and through March 31, 2024, Dr. Saoud was entitled to receive $27,000 for up to fifteen hours of consulting services per week for a four-week period. |
| 2023-04-28 | The first milestone was achieved on April 28, 2023, and as a result 88,077, 46,987 and 19,843 of the PRSUs vested with respect to each of Dr. Luthringer, Mr. Race and Mr. Ahlholm. |
| 2023-06-27 | On June 27, 2023, we entered into a securities purchase agreement (the Securities Purchase Agreement) with the Federated Hermes Kaufmann Funds and Boehringer Ingelheim International GmbH (collectively, the Investors), pursuant to which we agreed to issue and sell to the Investors in a private placement (the Private Placement) (i) an aggregate of 1,425,000 shares of our common stock, at a purchase price of $10.00 per share, and (ii) in lieu of additional shares of our common stock, pre-funded warrants to purchase an aggregate of 575,575 shares of common stock, at a purchase price of $9.99 per pre-funded warrant. |
| 2023-06-28 | The aggregate value of the Companys Common Stock held by non-affiliates of the Company was approximately $12.9 million as of June 28, 2024, when the last reported sales price was $3.19 per share. |
| 2023-06-30 | The Private Placement closed on June 30, 2023, as a result of which we received aggregate net proceeds of approximately $19.6 million after deducting offering expenses of approximately $0.4 million payable by us. |
| 2023-07-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Third Amendment effective July 1, 2023 |
| 2023-07-07 | This information is based partially on the information reported on the Schedule 13D filed by Boehringer AG (BI GP) and Boehringer Ingelheim International GmbH on July 7, 2023. |
| 2023-08-04 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Fourth Amendment effective August 4, 2023 |
| 2023-08-06 | Ms. Hilleman resigned from the Board effective August 6, 2024. |
| 2023-08-09 | Pursuant to the Securities Purchase Agreement, we filed a registration statement on Form S-3 (File No. 333-273686), which was declared effective by the SEC on August 9, 2023, covering the resale of the Registrable Securities (as such term is defined in the Securities Purchase Agreement). |
| 2023-08-29 | Boehringer Ingelheim International GmbH designated a board observer on August 29, 2023. |
| 2023-11 | In November 2023, our Board adopted a written compensation recovery policy in accordance with the Dodd-Frank Wall Street Reform and Consumer Protection Act and applicable Nasdaq rules, a copy of which is filed as an exhibit to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. |
| 2023-11-29 | Our Amended and Restated Non-Employee Director Compensation Plan, as adopted by our Board, became effective April 1, 2018 and was amended on November 29,2023. |
| 2024-01-01 | Effective January 1, 2024, Dr. Luthringer was entitled to an annual base salary of $649,064. |
| 2024-01-01 | Effective January 1, 2024, Mr. Race was entitled to an annual base salary of $492,018. |
| 2024-01-01 | Effective January 1, 2024, Mr. Ahlholm was entitled to an annual base salary of $400,000, which increased to $449,513 effective January 1, 2024. |
| 2024-01-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Fifth Amendment effective April 1, 2024 |
| 2024-01-18 | This information is based partially on the information reported on the Schedule 13G/A filed by Federated Hermes, Inc. (the Federated Hermes Parent) on January 18, 2024. |
| 2024-03-31 | The table below sets forth our executive officers and directors as of March 31, 2025. |
| 2024-04-01 | Effective April 1, 2024 and through December 31, 2024, Dr. Saoud was entitled to receive $30,000 for up to fifteen hours of consulting services per week for a four-week period. |
| 2024-04-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Fifth Amendment effective April 1, 2024 |
| 2024-08-06 | Ms. Hilleman resigned from the Board effective August 6, 2024. |
| 2024-12-04 | 25% of the shares subject to the option will vest and become exercisable on December 5, 2025 and the balance of the shares vest and become exercisable in a series of twelve equal quarterly installments upon the executive officers completion of each quarter of service over the three-year period thereafter. |
| 2024-12-05 | Our Amended and Restated Non-Employee Director Compensation Plan was further amended on December 5, 2024, which became effective on January 1, 2025. |
| 2024-12-31 | The Companys stock price, trading on The Nasdaq Capital Market under the symbol NERV, was $2.222 as of December 31, 2024. |
| 2025-01-01 | Our Amended and Restated Non-Employee Director Compensation Plan was further amended on December 5, 2024, which became effective on January 1, 2025. |
| 2025-01-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Sixth Amendment effective January 1, 2025 |
| 2025-01-01 | Effective January 1, 2025 and through March 31, 2025, Dr. Saoud was entitled to receive $30,000 for up to fifteen hours of consulting services per week for a four-week period. |
| 2025-03-31 | The following table sets forth certain information regarding the ownership of the Companys common stock as of March 31, 2025 |
| 2025-04-01 | Transition, Separation, and Consulting Agreement with Dr. Jay B. Saoud, Dr. Saoud and the Company entered into a Transition, Separation, and Consulting Agreement, as amended by that certain Seventh Amendment effective April 1, 2025 |
| 2025-04-01 | Effective April 1, 2025 and through April 30, 2025, Dr. Saoud will be entitled to receive $30,000 for up to fifteen hours of consulting services per week for a four-week period. |
| 2025-04-18 | The number of shares of Registrants Common Stock outstanding as of April 18, 2025 was 6,993,406. |
| 2025-04-21 | Date: April 21, 2025 |
| 2025-04-30 | Dr. Saouds consulting services will end on April 30, 2025, subject to termination or renewal. |
| 2030-10-12 | Option Expiration Date |
| 2032-02-15 | Option Expiration Date |
| 2032-12-12 | Option Expiration Date |
| 2033-10-03 | Option Expiration Date |
| 2034-12-04 | Option Expiration Date |
Keywords
executive compensation, directors, corporate governance, related party transactions, 10-K amendment, Minerva Neurosciences, beneficial ownership, equity compensation, audit fees
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.